Mr. Jerry Lai reports

PANGENOMIC HEALTH ANNOUNCES FINANCIAL RESULTS FOR HALF YEAR ENDED JUNE 30, 2023

Pangenomic Health Inc. has filed financial statements for the six-month period ended June 30, 2023.

The first half 2023 financial statements, together with detailed information regarding the company's financial results as set forth in the company's management's discussion and analysis for the same period, can be found under the company's profile at SEDAR.

Key highlights in the period included:

• Listed on the Aquis Stock Exchange (AQSE) in the United Kingdom;
• Introduced hormonal health support for women with the availability of the Women's Hormonal Health DNA Report;
• Launched e-commerce platform to market its proprietary natural herbal remedy information library and practitioner-vetted brands;
• Introduced rapid in-clinic access to patient Vitamin D assessments through the MUJN biomarker platform.

About Pangenomic Health Inc.

Pangenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company's initial focus is to support mental health. Registered as a British Columbia benefit company, Pangenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

We seek Safe Harbor.